Tanespimycin - Wikipedia
网页Tanespimycin (17-N-allylamino-17-demethoxygeldanamycin, 17-AAG) is a derivative of the antibiotic geldanamycin that is being studied in the treatment of cancer, specifically in younger patients with certain types of leukemia or solid tumors, especially kidney tumors.
Tanespimycin (17-AAG，坦螺旋霉素) - 仅供科研 | HSP90抑制剂
网页Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC 50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90. Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity.
Tanespimycin (17-AAG) | 坦螺旋霉素 | 购买HSP (HSP90) 抑制剂
网页Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) 是一种有效的 HSP90 抑制剂，无细胞试验中 IC50 为5 nM，作用于来自肿瘤细胞的HSP90比作用于来自正常细胞HSP90结合亲和力高100倍。. Tanespimycin (17-AAG)可诱导细胞凋亡、坏死、自噬和线粒体自噬。. Phase 3。. Tanespimycin (17-AAG ...
Spotlight on 17-AAG as an Hsp90 inhibitor for molecular
网页In this paper, we review preclinical and clinical research on 17-AAG as a single agent and in combination with other anticancer agents. In addition, we highlight the potential of using nanocarriers and nanocombination therapy to improve therapeutic effects of 17-AAG.
17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated …
网页2005年9月11日 · We examined the therapeutic effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG), a potent Hsp90 inhibitor, and its ability to degrade polyglutamine-expanded mutant AR.
Spotlight on 17‐AAG as an Hsp90 inhibitor for molecular targeted …
网页2019年1月29日 · In this paper, we review preclinical and clinical research on 17-AAG as a single agent and in combination with other anticancer agents. In addition, we highlight the potential of using nanocarriers and nanocombination therapy to …
17-AAG: mechanisms of antitumour activity - PubMed
网页This article discusses the mechanistic evidence underlying 17-AAG's cytostatic, proapoptotic, antiangiogenic and anti-invasive properties that provide the basis for its antitumour activity and underscores its unique therapeutic potential as a multi-targeted agent, as opposed to most of the current-generation molecular therapeutics.
The HSP90 inhibitor, 17AAG, protects the intestinal stem cell
网页2015年9月14日 · Since the HSP90 inhibitor 17-allylamino-demethoxygeldanamycin (17AAG) is developed in clinics, we explored here its ability to control intestinal acute GvHD in vivo in two mouse GvHD models...
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for
网页2006年2月16日 · 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a new anticancer agent currently in clinical trials. The ability of 17-AAG to abrogate the function of...
Frontiers | A Novel Mechanism of 17-AAG Therapeutic Efficacy on …
网页2021年1月24日 · Our current study revealed significant anti-tumor activity after HSP90 inhibition with the drug 17-AAG in the malignant, MYCN-amplified IMR-32 cells and more potent anti-tumor activity in the non-MYCN amplified SK-N-SH cells. 17-AAG treatment significantly inhibited cellular proliferation and viability in both cell lines at 72 and 96 h post ...